Clinical Production of Pharmaceutical Grade Tc-99m Dextran 70 for Lymphoscintigraphy

Lymphoscintigraphy is an established means to determine the lymphatic drainage patterns from malignant tissues and edematous extremities. Unfortunately, there are no commercially available dedicated radiopharmaceuticals labeled for use in lymphoscintigraphy studies. The authors report a simple way t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2000-03, Vol.25 (3), p.179-181
Main Authors: DANSEREAU, RAYMOND N, LINE, BRUCE R
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Cardiovascular system
Contrast media. Radiopharmaceuticals
Dextrans - chemistry
Drug Compounding
Humans
Investigative techniques, diagnostic techniques (general aspects)
Lymphoscintigraphy
Male
Medical sciences
Melanoma - diagnostic imaging
Melanoma - surgery
Organotechnetium Compounds - chemistry
Pharmacology. Drug treatments
Radionuclide investigations
Radiopharmaceuticals - chemistry
Skin Neoplasms - diagnostic imaging
Skin Neoplasms - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphoscintigraphy is an established means to determine the lymphatic drainage patterns from malignant tissues and edematous extremities. Unfortunately, there are no commercially available dedicated radiopharmaceuticals labeled for use in lymphoscintigraphy studies. The authors report a simple way to extemporaneously compound pharmaceutical-grade Tc-99m dextran 70 to meet this need. Pharmaceutical-quality Tc-99m dextran 70 injection is prepared by a simple rapid method from drug intermediates that are marketed as parenteral drug products. The radiolabeling process yields a product of high radiochemical purity, with good in vitro and in vivo stability. The authors illustrate the use of this product in a patient with melanoma to show the lymphatic drainage pattern before surgery. The method described permits rapid compounding of Tc-99m dextran 70 injection from drug components that are intended for parenteral administration. Tc-99m dextran 70 provides the option of performing lymphoscintigraphy in any clinical nuclear medicine setting.
ISSN:0363-9762
1536-0229
DOI:10.1097/00003072-200003000-00003